NYSEReal EstateReal Estate - ServicesSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
finalize partnership with India | Despite a 50% revenue drop in Q3 FY2026, a partnership with India could boost growth. | Improving | no partnership agreement signed within 12 months | Qualitative: India nearing finalization of RFP (May 2026); no signed agreement yet News from May 2026 indicates India is nearing finalization of the Rafael RFP ahead of high-level visits. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
move towards positive EPS | A primary condition in Rafael Holdings Inc's published investment case. The stated target is EPS >= 0. | Broken | EPS remains negative through FY27 | Diluted EPS: $-0.08 per share FY2026-Q3; GAAP. Published target: EPS >= 0. Target period is not explicitly aligned with this observation. Source published Jun 11, 2026-0.08 USD/share · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q3 · Period ending Apr 30, 2026 Source: company_financial_results. Reference: 65dbdbfd-bc67-439f-98e5-09b04e73a1ed. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
revenue growth recovers above -10% YoY | A primary condition in Rafael Holdings Inc's published investment case. The stated target is >= -10% YoY revenue growth. | Broken | YoY revenue growth remains below -10% in FY27 | Revenue growth: -50.55% FY2026-Q3; GAAP. Published target: >= -10% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Jun 11, 2026-50.552486 percent · calculatedSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q3 · Period ending Apr 30, 2026 Source: company_financial_results. Reference: 65dbdbfd-bc67-439f-98e5-09b04e73a1ed. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 4, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, centered on developing Trappsol Cyclo for NPC rather than an established commercial business. The long-term thesis is in a watch state, and confidence has fallen from medium to low.
The evidence snapshot provides no valuation measures or direct account of market expectations, so it is not possible to assess what the market already assumes or whether valuation is cheap, fair, or expensive versus peers. The evidence does show a loss-making business, but it does not quantify how that is reflected in expectations.
Near term, management says the pivotal Phase 3 trial is complete and plans to submit an NDA, a request for regulatory approval, in the fourth quarter of 2026. Commercial preparation is underway, but there is no commercial revenue yet, and the recent financial performance is weak. The main near-term risks are continued losses and limited evidence of progress beyond the planned filing.
Over the next one to three years, the thesis hinges on completing the planned NDA submission and advancing Trappsol Cyclo toward commercialization. The evidence gives limited detail on commercial readiness or intellectual property progress, making those areas uncertain. Sector conditions could also help or hinder: interest-rate cuts and strong results from real estate bellwethers are cited as favorable signals, while weaker results could remove that support.
RFL’s long-term thesis has a meaningful clinical and regulatory milestone ahead, but weak results, no commercial revenue, high risk, and low confidence leave the case uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.